Next Article in Journal
Altered Interoceptive Perception and the Effects of Interoceptive Analgesia in Musculoskeletal, Primary, and Neuropathic Chronic Pain Conditions
Next Article in Special Issue
ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells
Previous Article in Journal
Dysregulation of Endothelin-1: Implications for Health Disparities in Alzheimer’s Disease
Previous Article in Special Issue
Systems Biology and Experimental Model Systems of Cancer

Drug Repurposing for Triple-Negative Breast Cancer

GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avenida de la Ilustración, 18016 Granada, Spain
UGC de Oncología Médica, Complejo Hospitalario de Jaén, 23007 Jaén, Spain
Department of Legal Medicine, School of Medicine—PTS—University of Granada, 18016 Granada, Spain
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
J. Pers. Med. 2020, 10(4), 200;
Received: 24 September 2020 / Revised: 20 October 2020 / Accepted: 28 October 2020 / Published: 29 October 2020
(This article belongs to the Special Issue Recent Developments in Cancer Systems Biology)
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer which presents a high rate of relapse, metastasis, and mortality. Nowadays, the absence of approved specific targeted therapies to eradicate TNBC remains one of the main challenges in clinical practice. Drug discovery is a long and costly process that can be dramatically improved by drug repurposing, which identifies new uses for existing drugs, both approved and investigational. Drug repositioning benefits from improvements in computational methods related to chemoinformatics, genomics, and systems biology. To the best of our knowledge, we propose a novel and inclusive classification of those approaches whereby drug repurposing can be achieved in silico: structure-based, transcriptional signatures-based, biological networks-based, and data-mining-based drug repositioning. This review specially emphasizes the most relevant research, both at preclinical and clinical settings, aimed at repurposing pre-existing drugs to treat TNBC on the basis of molecular mechanisms and signaling pathways such as androgen receptor, adrenergic receptor, STAT3, nitric oxide synthase, or AXL. Finally, because of the ability and relevance of cancer stem cells (CSCs) to drive tumor aggressiveness and poor clinical outcome, we also focus on those molecules repurposed to specifically target this cell population to tackle recurrence and metastases associated with the progression of TNBC. View Full-Text
Keywords: triple-negative breast cancer; personalized medicine; computational methods; drug repurposing; clinical trials; cancer stem cells triple-negative breast cancer; personalized medicine; computational methods; drug repurposing; clinical trials; cancer stem cells
Show Figures

Graphical abstract

MDPI and ACS Style

Ávalos-Moreno, M.; López-Tejada, A.; Blaya-Cánovas, J.L.; Cara-Lupiañez, F.E.; González-González, A.; Lorente, J.A.; Sánchez-Rovira, P.; Granados-Principal, S. Drug Repurposing for Triple-Negative Breast Cancer. J. Pers. Med. 2020, 10, 200.

AMA Style

Ávalos-Moreno M, López-Tejada A, Blaya-Cánovas JL, Cara-Lupiañez FE, González-González A, Lorente JA, Sánchez-Rovira P, Granados-Principal S. Drug Repurposing for Triple-Negative Breast Cancer. Journal of Personalized Medicine. 2020; 10(4):200.

Chicago/Turabian Style

Ávalos-Moreno, Marta, Araceli López-Tejada, Jose L. Blaya-Cánovas, Francisca E. Cara-Lupiañez, Adrián González-González, Jose A. Lorente, Pedro Sánchez-Rovira, and Sergio Granados-Principal. 2020. "Drug Repurposing for Triple-Negative Breast Cancer" Journal of Personalized Medicine 10, no. 4: 200.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop